Skip to Main Content

Paper Details

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent manner.
bioRxiv
2
2023
CD8, CD8 T cells, CD8 effector T cells, Fas, Kras, Kras mutant protein, MRTX1133, Oncogenic Kras, PDAC, PDXs, PanINs, Pancreatic ductal adenocarcinoma, cancer, cancer associated fibroblasts, cancer cells, human, mouse, mutant Kras, patient, patients, pre-neoplastic pancreatic lesions, stromal fibroblasts, tumor

Datasets

Release 1.2